{"id":41279,"date":"2021-09-17T07:44:45","date_gmt":"2021-09-17T07:44:45","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=41279"},"modified":"2021-09-19T21:42:34","modified_gmt":"2021-09-19T21:42:34","slug":"trial-design-for-next-generation-prep","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/41279","title":{"rendered":"Trial design for next generation PrEP"},"content":{"rendered":"<div><\/div>\n<div>\n<p class=\"HTBsubhead3authorcredit\"><strong><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-40950\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/07\/IAS-logo-208x300.png\" alt=\"\" width=\"208\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/07\/IAS-logo-208x300.png 208w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/07\/IAS-logo.png 511w\" sizes=\"auto, (max-width: 208px) 100vw, 208px\" \/>HIV Forum<\/span><\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><b><span lang=\"EN-US\">The extremely high efficacy of current PrEP raises new challenges for next-generation PrEP.<\/span><\/b><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">Placebo-controlled studies are seen as unethical, now that oral PrEP should be standard of care prevention. It is also impractical to use randomised studies with active controls: whether for\u00a0non-inferiority or superiority endpoints, the studies would need to be too large. <\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">This satellite session organised by the HIV Forum discussed new approaches that are already being used in phase 3 PrEP studies using longer-acting drugs like islatravir and lenacapavir. The webcast is now online.<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Reference<\/span><\/p>\n<\/div>\n<div>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Innovative clinical trial designs to accelerate increase in PrEP choices. IAS\u00a02021 satellite session. 18 July 2021.<br \/>\n<\/span><a href=\"https:\/\/forumresearch.org\/hiv-forum\/prep-project\/meetings\">https:\/\/forumresearch.org\/hiv-forum\/prep-project\/meetings<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>HIV Forum The extremely high efficacy of current PrEP raises new challenges for next-generation PrEP. Placebo-controlled studies are seen as unethical, now that oral PrEP should be standard of care prevention. It is also impractical to use randomised studies with &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[313],"class_list":["post-41279","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-ias-2021"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=41279"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41279\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=41279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=41279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=41279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}